NEW YORK (GenomeWeb) – German start-up Oncgnostics recently raised €1 million ($1.1 million) to support clinical trials of an epigenetic assay called GynTect test for assessing cervical cancer risk.
The Jena-based firm raised €500,000 of the money via a crowdfunding mechanism called Seedmatch, with VC group and current investor, Beteiligungsmanagement Thüringen (BM-T) providing matching funds.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
